Why Agenus Stock Is Popping Today
Shares of Agenus (NASDAQ: AGEN), a clinical-stage immunotherapy company, rose by as much as 9.2% during the first half of Monday's trading session. The drugmaker's stock perked up in early morning action today in response to the news that the first COVID-19 patient had been dosed with agenT-797, an off-the-shelf cell therapy designed by its subsidiary AgenTus Therapeutics. The trial will evaluate the therapy in patients with moderate to severe symptoms.
The trial is reportedly being led by Dr. Koen van Besien at Weill Cornell Medical College/New York Presbyterian Hospital. Agenus, in the same press release, also noted that the the Food and Drug Administration (FDA) had cleared the therapy to begin trials in cancer patients. The biotech's shares have cooled off as today's session has progressed, but they are still up by a modest 2.67% as of 1:43 p.m. EST.
Image source: Getty Images.
Source Fool.com
